Argos Therapeutics (ARGS) Bouncing Back; Jefferies Ups View on Syngenta (SYT)


Shares of Argos Therapeutics, Inc. (Nasdaq:ARGS) soared more than 50% to touch the $3.17 mark in early trading Tuesday. However, there appears to be no relevant information in the street that may explain the rally of the company’s stock

An independent data monitoring committee recently suggested Argos Therapeutics the continuation of its ADAPT phase 3 clinical trial of AGS-003 in patients with metastatic renal cell carcinoma

ARGS stock is currently exchanging hands for about $2.68, up $0.63 (or +30.73%), and 722,973 of its shares were traded so far

Argos Therapeutics, an immuno-oncology company, has 20.74M Shares Outstanding and ARGS stock 52-week range is between $1.61 and $10.56 per share



Brokerage firm Jefferies upgraded Syngenta AG (NYSE:SYT) shares from a Hold to a Buy rating.

According to Bloomberg, China National Chemical Corp. recently increased its takeover offer for agrochemicals giant Syngenta to around $44 billion

SYT stock is currently trading at $78.54, up $2.26 (or +2.96%), and 1,115,237 of its shares exchanged hands so far, a large increase in activity versus its average volume (3m) of 600,484

Syngenta has 459.33M Shares Outstanding and SYT stock one-year range is from $61.61 to $98.15 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at